EGFR and lung adenocarcinoma: The discovery of activating epidermal growth factor receptor (EGFR) mutations as predictors of a response to EGFR tyrosine kinase inhibitor (TKI) therapy profoundly changed the therapeutic landscape of lung adenocarcinoma [3,4].